Filing Details

Accession Number:
0001410939-23-000007
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-01-04 18:33:37
Reporting Period:
2023-01-02
Accepted Time:
2023-01-04 18:33:37
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1410939 Iveric Bio Inc. ISEE Pharmaceutical Preparations (2834) 208185347
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1703623 Francis David Carroll C/O Iveric Bio, Inc.
8 Sylvan Way
Parsippany NJ 07054
Svp, Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-01-02 8,750 $0.00 72,074 No 4 M Direct
Common Stock Disposition 2023-01-03 3,602 $20.06 68,472 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2023-01-02 8,750 $0.00 8,750 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
26,250 No 4 M Direct
Footnotes
  1. Represents shares automatically sold pursuant to the prespecified terms of the applicable Restricted Stock Unit Agreement to satisfy the Reporting Person's minimum statutory withholding obligations with respect to the income recognized by the Reporting Person upon the vesting of the restricted stock units on January 2, 2023.
  2. The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $19.91 to $20.56 on January 3, 2023 on behalf of a group of employees of the Registrant to satisfy the payment of withholding tax liability of such employees. The Reporting Person undertakes to provide upon request by the staff of the Securities Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range.
  3. Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit.
  4. On December 16, 2021, the Reporting Person was granted 35,000 restricted stock units, which vests with respect to 25% of the shares subject to the award in annual installments (on January 2, 2023, January 2, 2024, January 2, 2025 and January 2, 2026), subject to continued employment with the Registrant and the other terms and conditions of the Registrant's 2013 Stock Incentive Plan.